The Queen’s University of Belfast Confidence in Concept programme 2018/19

Lead Research Organisation: Queen's University Belfast
Department Name: UNLISTED


Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding
Description Biomedical Catalysis 2021 R2 - AilseVax: AltRNA8V antigens for cancer vaccines
Amount £365,369 (GBP)
Funding ID 10025636 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2022 
End 03/2024
Description Development of vaccine to prevent Pseudomonas aeruginosa infection - North-South Research Programme 2021
Amount £3,000,000 (GBP)
Funding ID HEA North South 2021 - Strand II - AVIRT via UCD 
Organisation Higher Education Authority 
Sector Public
Country Ireland
Start 02/2022 
End 01/2026
Description Innovate UK Innovation Scholar Secondment for ECR Peter Stewart - awarded to Manuel Salto-Tellez
Amount £65,666 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 12/2020 
End 12/2021
Description Proof of Concept - Long-acting injectable peptide-like hydrogel implant for sustained delivery of HIV drug cabotegravir
Amount £125,827 (GBP)
Funding ID INI POC 1026 - LoO:2111/130282815 
Organisation Invest Northern Ireland 
Sector Public
Country United Kingdom
Start 11/2021 
End 10/2022
Description Queen's University Medicines Accelerator (QuMED) - Retention Funds
Amount £605,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2023 
End 07/2023
Description Small molecule inhibitors of the anti-apoptotic protein FLIP for the treatmentof cancer.
Amount £5,556,983 (GBP)
Funding ID 110371/Z/15/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2016 
End 09/2020
Description UKRI Innovate UK Innovation-to-Commercialisation of University Research (ICURe) SETsquared Award Cohort 32. Peptide hydrogel implants improve patient adherence to HIV/AIDs drugs.
Amount £30,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 01/2021 
End 06/2021
Description Uncovering the essential role of host hetero-hexameric ATPases in rhinovirus replication
Amount £492,568 (GBP)
Funding ID MR/X020371/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 07/2023 
End 07/2026
Description iCURE Discover Programme : Exploring the clinical and commercial potential of a vaccine to prevent Pseudomonas aeruginosa (Beckie Ingram)
Amount £3,700 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 08/2023 
End 11/2023
Description Collaborative Agreement - Daniel Longley & Ipsen 
Organisation Ipsen
Country Global 
Sector Private 
PI Contribution Collaboration and licensing agreement between QUB (LOngley, Harrison) and Ipsen for preclinical first in class FLIP inhibitor programme. Underlying work as part of CIC project led to this. The academic team at QUB, led by Professors Dan Longley and Tim Harrison, have developed novel, small molecule FLIP inhibitors and used these to achieve pre-clinical proof of concept, and the priority for the team is now to progress this program towards clinical development. Professor Longley commented "Our work to date strongly supports the potential for FLIP inhibitors as therapeutic agents in multiple oncology settings. Our team is looking forward to partnering with Ipsen's clinical and development experts, harnessing their global knowledge, expertise and networks to advance this program and bring a FLIP inhibitor to people living with cancer around the world." Prof Harrison added "We are excited about the potential of the novel, first in class small molecule FLIP inhibitors we have been able to develop thanks to the support from Wellcome, and now are looking forward to working with Ipsen to move these molecules through the next stages of development, and ultimately into new treatments for patients."
Collaborator Contribution This collaboration and licensing agreement provides Ipsen with a global exclusive licence to research, develop, manufacture, and commercialize FLIP inhibitors.
Impact WO2005053725A3
Start Year 2021
Company Name AilseVax 
Description AilseVax develops technology, such as an antigen discovery platform and adjuvant technology, with the aim to create new cancer vaccines. 
Year Established 2021 
Impact N/A
Company Name Univ8 Genomics 
Description Univ8 Genomics develops genomics products for the healthcare sector. 
Year Established 2019 
Impact The University and Company successfully secured a UKRI / Innovate UK Innovation Scholar Secondment grant, in order to place an experienced researcher into teh compmany for the purpose of validating these technologies and moving from an academic test into a commercial product